Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia
Cell stem cell, 2018-06, Vol.22 (6), p.951-959.e3 [Peer Reviewed Journal]2018 ;Copyright © 2018. Published by Elsevier Inc. ;ISSN: 1934-5909 ;EISSN: 1875-9777 ;DOI: 10.1016/j.stem.2018.05.018 ;PMID: 29859176
Full text available
|
||||
 |
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY |  |
(84-028) 37 755 057 | Feedback |
| 19 Nguyen Huu Tho St. Dist.7, HCM |  |
thuvien@tdtu.edu.vn | ||